1Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma [J]. Br J Cancer,2011,105(9) :1414-1418.
2Jezersek NB. Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010-a single centre report [ J ]. Radiol Oncol, 2012,46 ( 4 ) 346-353.
3Ghesquieres H,Drouet Y,Sunyach MP, et al. Evidence of time-de pendent prognostic factors predicting early death but not long- term outcome in primary CNS lymphoma: a study of 91 patients [J]. Hematol Oncol, 2013,31 (2) : 3 17-324.
4Ferreri AJ. How treat primary CNS lymphoma[J]. Blood, 20] 1, 118(3) :510-522.
6Sung KH, Lee EH, Kim YZ. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combi- nation chemotherapy for primary central nervous system lympho- ma[J]. J Korean Med Sci,2011,26(4) ..551-560.
8Valles FE, Perez-Valles CL, Regalado S, et al. Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immuno- competent patients with primary central nervous system lympho- ma[J]. AJNR,2013,34(1) :35-40.
9Plaza MJ, Borja MJ, Altman N, et al. Conventional and advanced MRI features of pediatric intracranial tumors:posterior fossa and suprasellar tumors[J]. A_JR, 2013,200(5) : 1115-1124.
10Lu SS,Kirn SJ,Kim HS,et al. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions[J]. AJNR, 2014,35 (2) .. 270-277.
8Guo AC, Cummings TJ, Dash RC, et al. Iymphomas and High-grade Astoeytomas:Comparison of Water Diffusibility and Histologic Charaeteristies[J]. Radiology,2002,224(1): 177-183.
9Gliemroth J,Kehler U,Gaebel C, et al. Neuroradiological Findings in Primary Cerebral Lymphomas of Non-AIDS Patients[J]. Clini Neurol Neurosurg, 2003,105 (1) : 78-86.
10Slone HW,Blake JJ,Shah R,et al. CT and MRI Findings of Intracranial LymphomaEJ ]. AJR,2005,184(5) : 1679-1685.
